Patty Jenkins explains why 'Wonder Woman 1984' has more humour than the first movie

·3 min read

Watch: The cast of Wonder Woman 1984 talk to Yahoo

By Kevin Polowy

If you like your superhero movies with a heftier dose of comedy, you might be in the camp that likes Wonder Woman 1984 even better than its record-setting 2017 predecessor.

Moving away from the battlefields and No Mans Lands of the WWI-set Wonder Woman and into the mega-malls of 1980s America, there’s an airier tone to the action, even if the stakes remain just as high.

That’s thanks to a combination of cast additions (with Pedro Pascal playing a frenetic oil tycoon whose ambitions threaten the fate of the Earth and Kristen Wiig as an awkward scientist-turned-powerful antagonist), fish-out-of-water shenanigans when Chris Pine’s Steve Trevor turns up to shock Gal Gadot’s Diana Prince and some good old-fashioned ‘80s fashion quips.

Read more: Wonder Woman 1984 lands early PVOD release in the UK

“I felt like we were doing the right thing with the first one — it was great to have the humour between Diana and Steve — but then it goes into heavier thematics and that was the right thing to do,” director and co-writer Patty Jenkins tells Yahoo Entertainment in a recent interview (watch above).

Patty Jenkins and Gal Gadot on the set of 'Wonder Woman 1984' (Warner Bros.)
Patty Jenkins and Gal Gadot on the set of 'Wonder Woman 1984' (Warner Bros.)

“The truth though is, I love a great balance in a superhero movie. And particularly Wonder Woman is such a light and loving and fun character, also played by a very funny actress.”

Jenkins especially wanted to find cast members with comedic chops like Wiig and Pascal after saying goodbye to Lucy Davis, the scene-stealing actress who played Trevor’s excitable secretary in the first film. “It was really important to me to find sparkly, great, funny people, who were also capable of great drama to put in this one,” the filmmaker explains.

A still from Wonder Woman 1984. (Warner Bros.)
A still from Wonder Woman 1984. (Warner Bros.)

Between an early sequence in which Wonder Woman saves a string of females from dangerous men, a would-be sexual assaulter being fent off and a heavy amount of gawking, cat-calling and harassment toward Diana and Wiig’s Barbara Minerva, it also feels like a film more determined to speak to sexism in our culture in addition to the character’s innate female empowerment.

That wasn’t necessarily by design, though.

“It wasn’t a goal,” Jenkins says. “It actually just was so particularly so true back then, it was hard to avoid.

A still from Wonder Woman 1984. (Warner Bros.)
A still from Wonder Woman 1984. (Warner Bros.)

“But beautiful women in the world walking [around] encounter all of this other stuff so it just kind of came naturally. Particularly when you’re inherently doing scenes where beautiful Gal Gadot is walking around crowds of people. You’d just be lying if you acted like men wouldn’t be hitting on her all the time. They would be.”

Wonder Woman 1984 is in UK cinemas now and on Premium Video on Demand (PVOD) in the UK and Ireland starting on 13 January.

Watch Jenkins talk about her upcoming gig directing Star Wars: Rogue Squadron:

— Videos produced by Jon San and edited by Jimmie Rhee

Latest Stories

  • Bank of Canada expects economy to shrink due to COVID-19 lockdowns

    The Bank of Canada is leaving its key benchmark interest rate unchanged at 0.25 per while predicting an economic contraction in the first quarter as further COVID-19 restrictions take their toll. “Canada’s economy had strong momentum through to late 2020, but the resurgence of cases and the reintroduction of lockdown measures are a serious setback,” said the Bank in a release. “Growth in the first quarter of 2021 is now expected to be negative.”

  • NFL conference championship picks: Do blowouts in the first meetings matter for the rematches?

    The Bills and Packers are looking for some revenge.

  • Stimulus Check Update: Biden to Push Additional Aid Upon Taking Office

    With Joe Biden set to be inaugurated today, Americans should soon know more about their likelihood of getting a third stimulus payment. In the spring of 2020, eligible recipients got a $1,200 stimulus check, and in late December of 2020, lawmakers passed a follow-up relief measure that provided $600 stimulus checks. Joe Biden, however, along with other lawmakers, felt that $600 follow-up payment fell short, especially given the number of Americans who are still without jobs.

  • Spectroscopy® Announces L. Robert Baker the Winner of the 2021 Emerging Leader in Atomic Spectroscopy Award

    Baker will be honored at the Spectroscopy® Virtual Symposium, ‘Atomic Spectroscopy in Practice,’ in February

  • Madrid explosion: ‘At least two dead’ after huge blast in Spanish church

    At least two people have been killed after a huge explosion in a Madrid church with rescue workers looking for more survivors. A loud explosion was heard in central Madrid on Wednesday, at just before 3pm in a local parish Virgen de la Paloma. Early reports suggest the explosion occurred when two people were checking a boiler, local broadcaster ABC reported.

  • Brexit: Government considers scrapping some EU labour laws

    Labour accuses Kwasi Kwarteng of "unpicking" workers' rights, as minister confirms he will review rules.

  • Artificial Organs Market Sales Are Expected To Surpass US$ 35 Billion by 2030, As Stated by insightSLICE

    PUNE, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The Global Artificial Organs Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, supply chain analysis, competitive landscape, and market composition analysis. The global artificial organs market was worth US$ 16.25 Billion in 2019 and is expected to reach US$ 37.7 Billion by 2030 at a CAGR of 8.0% through 2030. Artificial organ is a man-made organ tissue or a device that could replace the original human body organ and continue the same specific function as that of the organ replaced to enable the patient to continue having a normal life. Organ failure is one of the major causes of mortality across the world population. Bio-artificial organs can provide a prolonged life to the patients by substituting the failed/defective organs in the body. The replacement of the artificial organs is not only limited to the life support organs. The artificial organ implants can also be related to improve the individual’s quality of life. One of the ways to create artificial organs is to use the tissue engineering or cell therapy techniques. Also, medical device solutions based on optical, mechanical, or electrical technological characteristics can be used. View This Report With Table of Contents : https://www.insightslice.com/artificial-organs-market Over the past few years, significant innovations have been introduced in the medical technology, which in turn have impacted the development of artificial organs implantation. Rising number of patients with organ failures along with increase in the amount of people suffering from the chronic diseases are some of the major factors supporting the growth of the global artificial organs market. However, high cost and maintenance along with the concerns of possible infections and other side effects due to artificial organ implants are restraining the growth of the market. However, continuous developments in the field of medical technology coupled with extensive research and development activities and clinical trials would improve the quality of the artificial organs and reduce the risks after the implantations. Access The Sample Pages of This Report : https://www.insightslice.com/request-sample/556 Increase in demand for organ implants Rising number of people suffering from one or more than one organ failures is one of the major factors increasing the demand for artificial organ implants. Moreover, less amount of organ donation and long lists of people awaiting the organ implants are also supporting the growth of the market globally. For instance, in India, according to data published by Directorate General of Health Services (Dte.GHS) around 1.8 lakhs of people suffer from kidney failure every year. However, only 6000 renal implants are carried. Moreover, over 2 lakhs of people die from liver failure or liver cancer but only 1,500 liver transplants are done over the year on a global scale. Similarly, with ever increasing number of people dying due to heart failure, only a few heart transplants are performed each year. Low number of implants can be attributed to many factors including high costs, less number of donors, underdeveloped healthcare infrastructure, etc. All these factors are encouraging the development and innovations in implantations of artificial organs. This would support the growth of the market significantly in the coming few years. Related report : Global Endodontic Consumables Market : https://www.insightslice.com/endodontic-consumables-market Global Adaptive Optics Market : https://www.insightslice.com/adaptive-optics-market Global Cannabidiol Oil Market : https://www.insightslice.com/cannabidiol-oil-market Negligent number of organ donors increasing the demand for artificial organ implants Factors such as having actively spreading cancer, HIV, diabetes, heart or kidney disease prevent people from donating their organs. Thus, the number of people on the donors list is significantly less than those on the waiting list. For instance, according to U.S. Government Information on Organ Donation and Transplantation as of September 2020, there were more than 109 thousand of people on the waiting list for organ implants. However, only 39,718 transplants were carried in 2019. Moreover, there were only 19,257 organ donors in the U.S. less number of organ donors is significantly increasing the demand for artificial organ implants. Artificial organ implants would be able to help many people who are way ahead in the waiting list. High costs and underdeveloped healthcare infrastructure could restrain the market growth Although the organ implant may bring prolonged life to the patient, this also needs a lot of money to be put in. In U.S. average cost related to heart transplant is around US$ 1 million and for a kidney transplant the cost is around US$ 400,000 or more. Most of the times it is difficult, for the people to spend high amount on the transplant surgery. Apart from the high treatment cost, under-developed infrastructure in many countries is also one of the factors challenging the growth of the market. Lack of organ transplant and retrieval centers in such countries is limiting the people to reap the benefits of the organ transplant. Major players active in the global artificial organs market include Zimmer Biomet, Abbott Laboratories, Berlin Heart Gmbh, Boston Scientific Corporation, Ekso Bionics, Iwalk, Inc., SynCardia Systems, LLC., Medtronic, ABIOMED, INC, Biomet, Inc, Edward Lifesciences Corporation, Heartware International, Inc and Jarvik Heart, Inc among the others. Buy This Report : https://www.insightslice.com/buy-now/556 insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details please contact our research and consulting team at info@insightslice.com. Contact Us: Alex, insightSLICE Phone (USA) : +1 707 736 6633 Email address : alex@insightslice.com Web: www.insightslice.com

  • Treasury Bond Auction Announcement - RIKS 33 0321 - RIKB 23 0515

    SeriesRIKS 33 0321RIKB 23 0515ISINIS0000021251IS0000032191Maturity Date03/21/203305/15/2023Auction Date01/22/202101/22/2021Settlement Date01/27/202101/27/202110% addition01/26/202101/26/2021 On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%. Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government Debt Management website. For additional information please contact Oddgeir Gunnarsson, Government Debt Management, at +354 569 9635.

  • ProVen VCT plc: Interim Management Statement

    ProVen VCT plcInterim Management Statement for the three months ended 30 November 2020 ProVen VCT plc (the “Company”) presents an Interim Management Statement for the three month period ended 30 November 2020. The statement also includes relevant financial information between the end of the period and the date of this announcement. Performance Unaudited30 November 2020Unaudited31 August 2020Unaudited31 May 2020Audited29 February2020 PencePencePencePenceNet Asset Value per share (“NAV”)70.067.368.070.1Dividends paid to date*71.7570.2568.2568.25NAV plus dividends paid to date141.75137.55136.25138.35 *Dividends paid represent dividends paid since the consolidation of 5p Ordinary Shares into 10p Ordinary Shares in October 2012. Prior to this date, the Company paid dividends totalling 113.95p on the 5p Ordinary Shares. Dividends paid or declaredOn 29 October 2020, the Company announced an interim dividend for the year ended 28 February 2021 of 1.5p per share. This dividend was paid on 4 December 2020 to shareholders on the register at 13 November 2020. Investment portfolio summary at 30 November 2020 Portfolio summary Valuation Venture capital investments£’000Zoovu Limited (t/a Smart Assistant)6,931Infinity Reliance Limited (t/a My 1st Years)6,891Mycs GmbH6,127Monica Vinader Limited4,702MPB Group Limited4,482Written Byte Limited (t/a DeepCrawl)3,948Litchfield Media Limited4,128Thread, Inc.4,025Access Systems, Inc.3,808ContactEngine Limited3,470Other investments33,935 82,447 Cash at bank36,491Other net current assets243 Net Assets119,181 Quoted investments are valued at the closing bid price at 30 November 2020, discounted where appropriate. Unquoted investments are valued at fair values established using the International Private Equity and Venture Capital Valuation Guidelines. Investment activity during the three month period ended 30 November 2020 Investment additions £’000Written Byte Limited (t/a DeepCrawl)1,153Thread, Inc.250Poq Studio Limited184Papier Ltd150 1,737 Investment disposals CostMarket value at 1 September 2020 DisposalProceedsGainagainstcostRealisedloss in period £’000£’000£’000£’000£’000Written Byte Limited (t/a DeepCrawl)*146294288142(6) 146294288142(6) *Part-disposal of shares, which completed at the same time as the follow-on investment in the same company. The transaction was structured in this way in order to strengthen the Company’s overall position as a shareholder in the company. Investment activity from 1 December 2020 to the date of this announcement £’000Exonar Limited309 309 Investment disposals from 1 December 2020 to the date of this announcement There were no investment disposals in the period from 1 December 2020 to the date of this announcement. Changes to share capitalOrdinarySharesof 10p eachAs at 1 September 2020170,706,535Shares bought back during the 3 months to 30 November 2020(390,969)Shares issued during the 3 months to 30 November 2020-As at 30 November 2020170,315,566 In the period from 1 December 2020 to the date of this announcement, 241,508 Ordinary Shares were repurchased and subsequently cancelled. In addition, 646,450 Ordinary Shares were issued under the Company’s Dividend Reinvestment Scheme in relation to the dividend paid on 4 December 2020. Material eventsProVen VCT plc and ProVen Growth and Income VCT plc (the “Companies”) announced on 3 December 2020 that they had published a Prospectus (comprising Securities Note, Registration Document and Summary) in respect of a combined offer for subscription to raise up to £40,000,000 by way of an issue of new ordinary shares in the Companies, with an over-allotment facility of up to a further £20,000,000 payable in full in cash on application. Other than the matters described above, there were no material events during the period from 1 September 2020 to 30 November 2020 or in the period from 1 December 2020 to the date of this announcement. Further informationFurther information regarding the Company, can be found on Beringea's dedicated VCT website: www.provenvcts.co.uk or by contacting Beringea, the Investment Manager at provenvcts@beringea.co.uk or by telephone 020 7845 7820. Beringea LLPCompany SecretaryTelephone 020 7845 7820-End

  • Thousands of Women Will Wear Pearls to Celebrate Kamala Harris on Inauguration Day

    The Facebook group, Wear Pearls on Jan 20th, 2021, has over 450,000 members

  • NVIDIA Shield TV now supports PS5 and Xbox Series X/S controllers

    Connecting the controllers works as you’d expect: Turn on the Shield’s Bluetooth discovery mode, and then either press the pairing button on your Xbox controller, or the PlayStation and Share/Clip buttons on the DualSense. It’s surprising it took so long for NVIDIA to add support for these new gamepads, considering that they already support PC pairing. In addition to the usual bug fixes, NVIDIA says that the Shield update also adds the December 2020 Android security patch, as well as better IR volume support for the Shield remote with Denon receivers.

  • AP FACT CHECK: Trump's fiction in his goodbye to Washington

    WASHINGTON — In his final remarks as president, Donald Trump tried to take credit for accomplishments of his predecessor and even those to come under President Joe Biden. Falsehoods suffused his farewell remarks Wednesday morning and the night before, though he was spot on with this: “We were not a regular administration.” As well, in noting Americans were “horrified” by the storming of the Capitol this month, he brushed past the encouragement he had given to the mob in advance and his praise of the attackers as “very special” people while they were still ransacking the seat of power. A look at some of his statements to well-wishers at Joint Base Andrews en route to Florida on Wednesday and in his videotaped address Tuesday: COVID-19 TRUMP: “We got the vaccine developed in nine months instead of nine years or five years or 10 years, a long time. It was supposed to take a long time. ... We have two out, we have another one coming almost immediately.” — remarks Wednesday before leaving Washington. TRUMP: “Another administration would have taken three, four, five, maybe even up to 10 years to develop a vaccine. We did in nine months.” — address Tuesday. THE FACTS: Actually, the administration didn’t develop any vaccines. Pharmaceutical companies did. And one of the two U.S. companies that have come out with vaccines now in use did not take development money from the government. Trump’s contention that a vaccine would have taken years under a different administration stretches credulity. COVID-19 vaccines were indeed remarkably fast, but other countries have been developing them, too. A vaccine for the coronavirus is not a singular achievement of the United States, much less the Trump administration. U.S. drugmaker Pfizer developed its vaccine in partnership with Germany’s BioNTech, eschewing federal money for development, though benefitting from an advance commitment from Washington to buy large quantities if the vaccine succeeded. A vaccine by Moderna, from the U.S., is also in widespread use. But Britain’s AstraZeneca-Oxford vaccine is being administered in several countries, and vaccines from China and Russia are also in limited use. More than a dozen potential vaccines are in late stages of testing worldwide. ___ TRUMP: “We passed VA Choice.” — address Tuesday. THE FACTS: No, he did not get the Choice program passed. President Barack Obama did. Trump expanded it. The program allows veterans to get medical care outside the Veterans Affairs system under certain conditions. Trump has tried to take credit for Obama's achievement scores of times. ___ TAXES TRUMP: "We also got tax cuts, the largest tax cut and reform in the history of our country by far." — remarks Wednesday. TRUMP: “We passed the largest package of tax cuts and reforms in American history.” — address Tuesday. THE FACTS: His tax cuts are not close to the biggest in U.S. history. It’s a $1.5 trillion tax cut over 10 years. As a share of the total economy, a tax cut of that size ranks 12th, according to the Committee for a Responsible Federal Budget. President Ronald Reagan’s 1981 cut is the biggest, followed by the 1945 rollback of taxes that had financed World War II. Post-Reagan tax cuts also stand among the historically significant: President George W. Bush’s cuts in the early 2000s and Obama’s renewal of them a decade later. ___ ECONOMY TRUMP: “We have the greatest economy in the world.” — remarks Wednesday. TRUMP: “We also built the greatest economy in the history of the world.” — address Tuesday. THE FACTS: No, the numbers show it wasn’t the greatest in U.S. history. And he is the first president since Herbert Hoover in the Depression to leave office with fewer jobs than when he started. Did the U.S. have the most jobs on record before the pandemic? Sure, the population had grown. The 3.5% unemployment rate before the recession was at a half-century low, but the percentage of people working or searching for jobs was still below a 2000 peak. Nobel Prize-winning economist Paul Romer looked at Trump’s economic growth record. Growth under Trump averaged 2.48% annually before the pandemic, only slightly better than the 2.41% gains achieved during Obama’s second term. By contrast, the economic expansion that began in 1982 during Reagan’s presidency averaged 4.2% a year. ___ TRUMP, on the economy after the pandemic: “It's a rocket ship up.” — remarks Wednesday. THE FACTS: Not so. There’s been no dramatic, V-shaped economic recovery under Trump. Employers cut jobs during his final December in office. But economists say the additional aid approved in December and the prospect of more from Biden could cause the strongest growth this year in more than two decades. ___ TRUMP: "We reignited America’s job creation and achieved record-low unemployment for African Americans, Hispanic Americans, Asian Americans, women — almost everyone. — address Tuesday. THE FACTS: Not an ignition. Job creation actually slowed in 2017, Trump’s first year in office, to about 2 million, compared with nearly 2.5 million in 2016, Obama’s last year in office. The low unemployment rates refer to a pre-pandemic economy that is no more. The pandemic has cost the U.S. economy 10 million jobs and has made Trump the first president since Hoover to oversee a net loss of jobs. The U.S. has about 2.8 million fewer jobs now than when Trump was inaugurated, and lost 140,000 just in December. And the job losses have fallen disproportionately on Black Americans, Hispanics and women. ___ TRUMP: “We rebuilt the American manufacturing base, opened up thousands of new factories, and brought back the beautiful phrase Made in the USA.” — address Tuesday. THE FACTS: That's a stretch. There are now 60,000 fewer manufacturing jobs in the U.S. than when Trump took office. Despite gains before the pandemic, the manufacturing base had not exactly been “rebuilt.” Before the coronavirus, nearly 500,000 manufacturing jobs were added under Trump, somewhat better than the nearly 400,000 gained during Obama’s second term. Still, even before the pandemic, the U.S. had 4.3 million fewer factory jobs than it did in 2001, the year China joined the World Trade Organization and a flood of cheaper imports from that country entered the U.S. ___ CAPITOL INSURRECTION TRUMP: “All Americans were horrified by the assault on our Capitol. Political violence is an attack on everything we cherish as Americans. It can never be tolerated.” — address Tuesday. THE FACTS: That may sum up the reaction of most Americans but it ignores his own part in stirring the anger of his supporters before they staged the violent melee. For months, Trump falsely claimed the November election was stolen, then invited supporters to Washington and sent them off to the Capitol with the exhortation to “fight like hell.” With the uprising still underway and the velocity of the attack apparent from video and reports from the scene, Trump released a video telling them “to go home now” while repeating “this was a fraudulent election” and adding: “We love you. You're very special.” The House impeached Trump, accusing him of inciting an insurrection. Senate Republican leader Mitch McConnell, a Trump political ally for four years, said Tuesday the Trump supporters were “fed lies” and ”provoked by the president and other powerful people." ___ MILITARY TRUMP: “We rebuilt the United States military.” — remarks Wednesday. THE FACTS: That’s an exaggeration. It’s true that his administration accelerated a sharp buildup in defence spending, including a respite from what the U.S. military considered to be crippling spending limits under budget sequestration. But a number of new Pentagon weapons programs, such as the F-35 fighter jet, were started years before the Trump administration. And it will take years for freshly ordered tanks, planes and other weapons to be built, delivered and put to use. The Air Force’s Minuteman 3 missiles, a key part of the U.S. nuclear force, for instance, have been operating since the early 1970s and the modernization was begun under the Obama administration. They are due to be replaced with a new version, but not until later this decade. ___ TRUMP: “We obliterated the ISIS caliphate.” — address Tuesday. THE FACTS: His suggestion of a 100% defeat is misleading as the Islamic State group still poses a threat. IS was defeated in Iraq in 2017, then lost the last of its land holdings in Syria in March 2019, marking the end of the extremists’ self-declared caliphate. Still, extremist sleeper cells have continued to launch attacks in Iraq and Syria in recent weeks and are believed to be responsible for targeted killings against local officials and members of the Syrian Democratic Forces. The continued attacks are a sign that the militant group is taking advantage of governments otherwise focused on the pandemic and the ensuing slide into economic chaos. The virus is compounding longtime concerns among security and U.N. experts that the group will stage a comeback. ___ CHINA TRUMP: “We imposed historic and monumental tariffs on China. ... Our trade relationship was rapidly changing, billions and billions of dollars were pouring into the U.S., but the virus forced us to go in a different direction.” — address Tuesday. THE FACTS: That’s a familiar assertion, false to the core. It’s false to suggest the U.S. never collected tariffs on Chinese goods before he took action. Tariffs on Chinese goods are simply higher in some cases than they were before. It’s also wrong to suggest that the tariffs are being paid by China. Tariff money coming into the government’s coffers is mainly from U.S. businesses and consumers, not from China. Tariffs are primarily if not entirely a tax paid domestically. ___ Associated Press writers Josh Boak, Robert Burns and Lolita C. Baldor contributed to this report. ___ EDITOR'S NOTE — A look at the veracity of claims by political figures. ___ Find AP Fact Checks at http://apnews.com/APFactCheck Follow @APFactCheck on Twitter: https://twitter.com/APFactCheck Hope Yen, Christopher Rugaber And Calvin Woodward, The Associated Press

  • Jill Biden and Vice President-Elect Sport Small Designer Labels for the Inaugural

    The incoming First Lady and the Vice President-elect selected styles from up-and-coming designers.

  • Johnson has ‘full confidence’ in Patel despite clash over pandemic border closures

    Prime minister refuses to tell MPs why he overruled home secretary

  • Kraft Heinz's High Dividend Really Is Too Good to Be True

    While Kraft Heinz's results have received a boost from more people staying at home, it still faces the same issues as we enter a "new normal."

  • Kering: Statement in compliance with article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)

    January 20, 2021 Statement in compliance with article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers) Date Total Number ofshares Total number of voting rights theoretical 1 Exercisable 2 January 15, 2021 125,017,916 177,784,151 177,657,876 1 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). 2 Excluding treasury shares stripped of voting rights. Attachment KERING - DRTSVTANG 15.01.2021

  • Green Hygienics Holdings Inc. To Host Shareholder Update Jan. 28, 2021

    SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company") is pleased to announce it will host a shareholder update call. The call will be facilitated by Green Hygienics’ CEO Ron Loudoun. He will be joined by COO Kyle MacKinnon. The team will provide an update on the Company’s achievements over the past year, current initiatives and projects, sales and the future road map. The call will take place on Thursday, Jan. 28, at 1 p.m. Pacific Standard Time/4 p.m. Eastern Time Investors, analysts and other interested parties can access the call through this Zoom Webinar link: https://zoom.us/j/98787053234?pwd=VmVnWkJHRDNRc0pBczlVZ3VFR0I3UT09 Webinar ID: 987 8705 3234 Passcode: 550001 Or Telephone: (for higher quality, dial a number based on your current location): US: +1 669-900-6833 or +1 929-205-6099 or +1 253-215-8782 or +1 301-715-8592 or +1 312-626-6799 or +1 346-248-7799 International numbers available: https://zoom.us/u/aoRrwoMMk The Company will answer questions at the conclusion of prepared remarks. Investors are asked to submit their questions to ir@greenhygienics.com About Green Hygienics Holdings Inc. Green Hygienic Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”), is a California based, innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids. The corporate mission is to adhere to the highest standards of operations in consistently delivering safe and premium quality products to consumers as well as to partnering with CPG (consumer-packaged-goods) and pharmaceutical companies. The Company intends to be a leader in compliances and capabilities in the hemp and cannabinoid supply marketplace. Using state of the art technologies, Green Hygienics intends to open a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability. We are building a team of visionary agrotechnology, pharmaceutical, and life scientists working at the intersection of nutraceutical, cosmeceutical, and pharmaceutical technologies with a goal to improve lives. For more information, please visit: www.GreenHygienics.com Corporate Video Link Company Contact: Green Hygienics Holdings Inc. 1.855.802.0299 Toll Free IR@GreenHygienics.com CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Corporate Communications:InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

  • Inauguration Day 2021 – live: Pence, Obamas and Bushes take their seats for Biden’s swearing-in ceremony

    Live news and updates

  • French officials call to ban far-right group after Pyrénées anti-migrant stunt

    Several officials of France’s southern Occitanie region have denounced an anti-migrant demonstration conducted in the Pyrénées Mountains by the far-right Génération Identitaire, a group subject to frequent calls for bans. French officials call to ban far-right group after Pyrénées anti-migrant stuntSeveral officials of France’s southern Occitanie region have denounced an anti-migrant demonstration conducted in the Pyrénées Mountains by the far-right Génération Identitaire, a group subject to frequent calls for bans.French police said some 30 people in pickup trucks bearing the far-right group’s “Defend Europe” logo set up on the Col du Portillon pass on the Franco-Spanish border, with some members going into the mountains and using a drone to monitor the border.Some of the far-right activists were removed from a hydroelectric dam at nearby Melles during an action the group said was to counter the “terrorist and migratory risk in the Pyrénées”.The operation lasted a few hours but received considerable media attention and criticism from some of the region’s top public officials.“This operation, completely illegal, was just a way of creating a buzz in the media and to allow these extremists to develop their hateful discourse,” read a statement signed by regional president Carole Delga and other officials, many from the Socialist Party.“I have asked the prefect of Occitanie to immediately and definitively put an end to this show of strength that runs contrary to the values of the Republic and our territory,” Delga wrote on Twitter. “This far-right coup must be banned by the interior ministry.”State officials in the Haute-Garonne department were more mitigated, saying the incident was “purely symbolic and caused no trouble to public order but which unnecessarily involved an intervention of the security forces, turning them away from their mission of monitoring the border”, according a statement from prefect Etienne Guyot.Reinforced border patrolsFrance and Spain are members of the European Union’s Schengen area, which guarantees free movement across borders of member states.French police have been watching border crossings more closely since early November, after President Emmanuel Macron reinforced monitoring “against terrorism, trafficking and immigration” following deadly and apparently jihadist-inspired attacks against schoolteacher Samuel Paty in the Paris region and three churchgoers in Nice.The prefecture in the Haute-Garonne decided in early January to close the Col du Portillon, which had become an entry point for undocumented migrants crossing on foot.On its Telegram social media account, Génération Identitaire posted images of its members wearing blue caps and jackets and driving three Toyota pickup trucks on mountain roads.“We are there to keep a close watch on how these measures are applied and to help the police forces to prevent migrants from entering France,” read a message posted in four languages, including English.History of anti-migrant actions The action came a month after an appeals court in Grenoble overturned convictions for the group and three of its members over a similar operation in the Alps, along the Franco-Italian, in 2018.The group and the three members had been found guilty of “exercising an activity in conditions whose nature created confusion with a public service” for their roles in actions in which about a hundred members of the group, with two helicopters and several pickup trucks blocked migrant routes in the mountains.The court overturned six-month prison sentences and 2,000-euro fines for the members and a 75,000-euro fine for the group.Génération Identitaire was founded in 2012 as part of an “identitarian” trend on the French far-right.In 2017, it joined other European far-right groups in chartering a ship aiming to stop NGO vessels from rescuing migrants in the Mediterranean Sea.France’s government receives frequent calls for the group to be banned.

  • Global Next Generation Centrifuge Industry

    Global Next Generation Centrifuge Market to Reach $1. 3 Billion by 2027. Amid the COVID-19 crisis, the global market for Next Generation Centrifuge estimated at US$941. 6 Million in the year 2020, is projected to reach a revised size of US$1.New York, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Next Generation Centrifuge Industry" - https://www.reportlinker.com/p05957510/?utm_source=GNW 3 Billion by 2027, growing at aCAGR of 4.7% over the period 2020-2027. Refrigerated Centrifuges, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$964 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ambient Centrifuges segment is readjusted to a revised 3% CAGR for the next 7-year period. The U.S. Market is Estimated at $277.4 Million, While China is Forecast to Grow at 4.4% CAGR The Next Generation Centrifuge market in the U.S. is estimated at US$277.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$229.2 Million by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.We bring years of research experience to this 6th edition of our report. The 184-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, Corning, Inc.Danaher CorporationEppendorf AGHettich Holding GmbH & Co. oHGHitachi Koki Co., Ltd.NuAireQiagen NVThermo Fisher Scientific, Inc. Read the full report: https://www.reportlinker.com/p05957510/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Global Competitor Market Shares Next Generation Centrifuge Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Next Generation Centrifuge by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 2: World Historic Review for Next Generation Centrifuge by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 3: World 15-Year Perspective for Next Generation Centrifuge by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Refrigerated Centrifuges by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 5: World Historic Review for Refrigerated Centrifuges by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 6: World 15-Year Perspective for Refrigerated Centrifuges by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Ambient Centrifuges by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 8: World Historic Review for Ambient Centrifuges by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 9: World 15-Year Perspective for Ambient Centrifuges by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 11: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 12: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Academic and Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 14: World Historic Review for Academic and Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 15: World 15-Year Perspective for Academic and Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Biopharmaceuticals Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 17: World Historic Review for Biopharmaceuticals Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 18: World 15-Year Perspective for Biopharmaceuticals Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 20: World Historic Review for Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 21: World 15-Year Perspective for Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 23: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 24: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Next Generation Centrifuge Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 25: USA Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 26: USA Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 27: USA 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 28: USA Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 29: USA Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 30: USA 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 CANADA Table 31: Canada Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 32: Canada Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 33: Canada 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 34: Canada Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 35: Canada Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 36: Canada 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 JAPAN Table 37: Japan Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 38: Japan Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 39: Japan 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 40: Japan Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 41: Japan Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 42: Japan 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 CHINA Table 43: China Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 44: China Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 45: China 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 46: China Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 47: China Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 48: China 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures European Next Generation Centrifuge Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 49: Europe Current & Future Analysis for Next Generation Centrifuge by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 50: Europe Historic Review for Next Generation Centrifuge by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 51: Europe 15-Year Perspective for Next Generation Centrifuge by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 53: Europe Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 54: Europe 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 55: Europe Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 56: Europe Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 57: Europe 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 FRANCE Table 58: France Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 59: France Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 60: France 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 61: France Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 62: France Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 63: France 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 GERMANY Table 64: Germany Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 65: Germany Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 66: Germany 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 67: Germany Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 68: Germany Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 69: Germany 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 ITALY Table 70: Italy Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 71: Italy Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 72: Italy 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 73: Italy Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 74: Italy Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 75: Italy 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 76: UK Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 77: UK Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 78: UK 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 79: UK Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 80: UK Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 81: UK 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 REST OF EUROPE Table 82: Rest of Europe Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 83: Rest of Europe Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 84: Rest of Europe 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 85: Rest of Europe Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 86: Rest of Europe Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 87: Rest of Europe 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 88: Asia-Pacific Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 89: Asia-Pacific Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 90: Asia-Pacific 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 91: Asia-Pacific Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 92: Asia-Pacific Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 93: Asia-Pacific 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 REST OF WORLD Table 94: Rest of World Current & Future Analysis for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 95: Rest of World Historic Review for Next Generation Centrifuge by Product Type - Refrigerated Centrifuges and Ambient Centrifuges Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 96: Rest of World 15-Year Perspective for Next Generation Centrifuge by Product Type - Percentage Breakdown of Value Sales for Refrigerated Centrifuges and Ambient Centrifuges for the Years 2012, 2020 & 2027 Table 97: Rest of World Current & Future Analysis for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 98: Rest of World Historic Review for Next Generation Centrifuge by End-Use - Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 99: Rest of World 15-Year Perspective for Next Generation Centrifuge by End-Use - Percentage Breakdown of Value Sales for Hospitals, Academic and Research Institutes, Biopharmaceuticals Companies, Contract Research Organization and Diagnostic Centers for the Years 2012, 2020 & 2027 IV. COMPETITION Total Companies Profiled: 46Read the full report: https://www.reportlinker.com/p05957510/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001